Weekly Injection Shows Real Promise for Cutting Back Heavy Drinking

Altimmune just shared some encouraging news. Its experimental drug pemvidutide helped people cut back on heavy drinking in a mid-stage clinical trial. And the results looked strong enough to turn heads on Wall Street.

The company ran the study, called RECLAIM, with 100 participants. Half received pemvidutide. Half got a placebo. Everyone in the trial had been diagnosed with alcohol use disorder.

So what counts as heavy drinking here? Researchers used a standard definition: five or more drinks in a day for men, four or more for women. They tracked how often that happened before and during treatment.

After 24 weeks, the numbers told a clear story. People on pemvidutide cut their heavy drinking days by 4.20 per week on average. The placebo group also improved, but by less: 2.75 days. Altimmune called the difference between groups highly statistically significant.

The drug didn’t just win on the main goal, either. It also performed well on several secondary measures. More patients on pemvidutide reached zero heavy drinking days by the end of the study. Alcohol abstinence rates improved too. So did a biomarker called phosphatidyl ethanol, which reflects how much alcohol someone has actually consumed.

Tolerability looked solid overall, according to the company. That matters, since side effects often determine whether patients stick with a treatment long enough for it to help.

There’s an interesting regulatory backstory here. Until recently, drug developers had to prove complete abstinence or zero heavy drinking days to win FDA approval for alcohol use disorder treatments. Last year, the agency opened up a new path, agreeing to accept a two-level drop in WHO risk drinking levels as a valid trial endpoint. That change gives companies like Altimmune more flexibility in how they design and measure success in these trials.

Why might pemvidutide work particularly well here? It targets two receptors at once, GLP-1 and GIP, rather than just one. Altimmune’s chief medical officer, Christophe Arbet-Engels, pointed to the liver-related effects tied to GIP signaling. Alcohol use disorder often damages the liver, so a drug that supports liver health alongside reducing cravings could offer a real advantage.

Analysts at Truist Securities seem to agree. They noted that roughly 90% of people with alcohol use disorder eventually develop liver steatosis. Many also deal with obesity, high blood pressure, or high cholesterol. A treatment that addresses multiple issues at once could prove genuinely valuable for this patient population.

Altimmune isn’t stopping here. The company plans to request an end-of-Phase 2 meeting with the FDA soon. That conversation will help shape what comes next for pemvidutide. Researchers also plan to present the full RECLAIM findings at an upcoming scientific conference, with a peer-reviewed publication expected to follow.

It’s worth remembering that pemvidutide is still experimental. It hasn’t been approved for alcohol use disorder or any other condition, and it isn’t available by prescription yet. Anyone looking for support today can still find quality, affordable options through the NIAAA’s treatment navigator. Larger, longer trials will need to confirm these results before regulators can even consider approval.

Altimmune isn’t working in a vacuum, either. Eli Lilly has two Phase 3 trials underway for its own GLP-1/GIP drug, brenipatide, targeting this same condition. A newer company called Baseline Therapeutics launched earlier this year with similar ambitions, and plans to move into late-stage trials soon.

Beyond drinking, Altimmune is also testing pemvidutide for MASH, a liver condition closely tied to type 2 diabetes and metabolic disease. Earlier results there looked promising, too, with meaningfully better disease resolution compared to placebo.

Investors clearly liked what they saw. Altimmune’s stock jumped as much as 19% in premarket trading following the announcement.